Page 9 - Cingulate Inc News Today

Go-to-Market Solution Provides Full Commercial Support for the First, True Entire Active-Day Medication Designed to treat ADHD Indegene Model Geared for Efficient National Commercial Launch in Multibillion-Dollar

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping over 300 points on Friday. The Dow traded down 1.07% to 32,798.91...

U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 450 points on Friday. The Dow traded down 1.39% to 32,692.94 wh...

/PRNewswire/ -- A latest research report [115+] pages with 360-Degree visibility, titled "Attention Deficit Hyperactivity Disorder Market Share, Size, Trends,...

Trial Results Expected 1H 2023 Company to Host Investor and Business Development Meetings Adjacent to Upcoming J.P. Morgan Healthcare Conference in...

19.09.2022 - Data Demonstrated Ability of CTx-2103 to Deliver a Single Administration of Triple-Release Buspirone – Setting the Stage for Future Trials Employing Cingulate’s Precision Timed Release (PTR) Technology CTx-2103 has the Potential to be the First ... Seite 1

11.08.2022 - $5 Million of Non-Dilutive FinancingVeteran Biotech Executive Appointed to Board KANSAS CITY, Kan., Aug. 11, 2022 (GLOBE NEWSWIRE) - Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision ...

KC Business Veteran, Two-Time Award Winner, Helped Lead Cingulate to 2021 IPO...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Press release content from Globe Newswire. The AP news staff was not involved in its creation.